Bafna Pharmaceuticals Ltd vs Jfl Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 135.7 as of 30 Apr 15:30 . The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 55.8 on March 2021 to 42.6 on March 2025 . This represents a CAGR of -5.26% over 5 yearsThe P/E Ratio of JFL Life Sciences Ltd changed from 12.9 on March 2023 to 13.9 on March 2025 . This represents a CAGR of 2.52% over 3 years The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 324.8 crore on March 2021 to ₹ 177.42 crore on March 2025 . This represents a CAGR of -11.39% over 5 yearsThe Market Cap of JFL Life Sciences Ltd changed from ₹ 36.29 crore on March 2023 to ₹ 57.58 crore on March 2025 . This represents a CAGR of 16.63% over 3 years The revenue of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 39.51 crore as compare to the Sep '25 revenue of ₹ 36.65 crore. This represent the growth of 7.8% The revenue of JFL Life Sciences Ltd for the Dec '25 is ₹ 26.85 crore as compare to the Sep '25 revenue of ₹ 29.92 crore. This represent the decline of -10.26% The ebitda of Bafna Pharmaceuticals Ltd for the Dec '25 is ₹ 4.27 crore as compare to the Sep '25 ebitda of ₹ 5.46 crore. This represent the decline of -21.79% The ebitda of JFL Life Sciences Ltd for the Dec '25 is ₹ 3.36 crore as compare to the Sep '25 ebitda of ₹ 2.93 crore. This represent the growth of 14.68% The net profit of Bafna Pharmaceuticals Ltd changed from ₹ -0.72 crore to ₹ 1.84 crore over 7 quarters. This represents a CAGR of NaN% The net profit of JFL Life Sciences Ltd changed from ₹ 1.91 crore to ₹ 2.02 crore over 7 quarters. This represents a CAGR of 3.25% The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of JFL Life Sciences Ltd changed from 8.33 % on March 2024 to 0 % on March 2025 . This represents a CAGR of -100.00% over 2 years .

About Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and is engaged in the manufacturing of pharmaceutical formulations of Betalactum and Non Betalactum products.
The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a.
Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern.
During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products.

About JFL Life Sciences Ltd

JFL Life Sciences Limited was incorporated as JFL Life Sciences Private Limited' on April 25, 2010 as a Private Limited Company.
Pursuant to a Special Resolution held on February 10, 2022, Company converted from a Private Limited to Public Limited Company and name of the Company was changed to JFL Life Sciences Limited', on March 3, 2022.
The Company manufactures and market pharmaceutical products.
The major products are Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet and capsules (General) and Oral Rehydration Solutions (ORS). In August 2022, the Company launched an IPO of 29,78,000 Equity Shares by raising funds aggregating to Rs. 18.16 Crore. The Company export products to African countries, Middle Eastern countries and CIS countries, mainly through merchant exporters.

FAQs for the comparison of Bafna Pharmaceuticals Ltd and JFL Life Sciences Ltd

Which company has a larger market capitalization, Bafna Pharmaceuticals Ltd or JFL Life Sciences Ltd?

Market cap of Bafna Pharmaceuticals Ltd is 321 Cr while Market cap of JFL Life Sciences Ltd is 62 Cr

What are the key factors driving the stock performance of Bafna Pharmaceuticals Ltd and JFL Life Sciences Ltd?

The stock performance of Bafna Pharmaceuticals Ltd and JFL Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bafna Pharmaceuticals Ltd and JFL Life Sciences Ltd?

As of May 4, 2026, the Bafna Pharmaceuticals Ltd stock price is INR ₹135.7. On the other hand, JFL Life Sciences Ltd stock price is INR ₹9.4.

How do dividend payouts of Bafna Pharmaceuticals Ltd and JFL Life Sciences Ltd compare?

To compare the dividend payouts of Bafna Pharmaceuticals Ltd and JFL Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.